Get notified when REPL files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Critical incident detected

Existential event

Time-sensitive event — see the red-flag panel below for the source-quoted detail.

Red Flags Detected

  • Going Concern (new) — The company's auditor and management both state substantial doubt about its ability to continue as a going concern.
  • Single Product Dependence (new) — TUDRIQEV is the company's only approved product, and its revenue prospects are wholly dependent on successful commercialization and confirmatory trial results.
  • Accelerated Approval Risk (new) — TUDRIQEV's approval is conditional on confirmatory trials; failure could lead to withdrawal of approval.
  • Dilution (new) — New investors face immediate dilution of $9.18 per share, and the offering excludes additional shares underlying pre-funded warrants.
NASDAQ: REPL Replimune Group, Inc. 424B5

Replimune prices $150M offering of 9.7M shares and pre-funded warrants at $12.06

Filed August 10, 2026 · ~1 min read

Key Changes

  • high

    Replimune is selling 9,701,490 shares at $12.06 and pre-funded warrants for 2,736,340 shares at $12.0599, for total gross proceeds of $150.0M before discounts.

    The Offering verify on EDGAR →
  • high

    The company estimates net proceeds of $140.5M after underwriting discounts and expenses, to fund TUDRIQEV launch, RPx platform development, and working capital.

    Use of Proceeds verify on EDGAR →
  • high

    Replimune reported a GAAP net loss of $313.9M for fiscal 2026 and an accumulated deficit of $1.26B; its auditor has expressed substantial doubt about its ability to continue as a going concern.

    Risk Factors verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.

Partner

Trade REPL commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify